Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

NCI Director Harold Varmus Resigns

March 4th 2015

The Nobel Prize winning director of the National Cancer Institute, Harold Varmus, MD, has tendered his resignation to pursue research interests in New York.

GSK, Novartis Product Exchange Completed

March 2nd 2015

GlaxoSmithKline (GSK) and Novartis have announced that a multi-billion-dollar, 3-pronged deal to exchange and share various operations has been completed.

Heterogeneity Complicates Treatment Decisions in Breast Cancer

February 28th 2015

Heterogeneity, which can result in treatment resistance, is commonly underestimated and misunderstood, representing an important area of future research.

Future Treatment Strategies for NSCLC

February 27th 2015

Development of Rociletinib and AZD9291 in NSCLC

February 27th 2015

Third-Generation EGFR Inhibitors in NSCLC

February 27th 2015

Personalized Medicine in NSCLC

February 27th 2015

Clinical Utility of PD-L1 as a Biomarker in Lung Cancer

February 27th 2015

Immunotherapy in Non-Small Cell Lung Cancer

February 27th 2015

Intricacies of Checkpoint Inhibition in NSCLC

February 27th 2015

Promise of Immunotherapy in Lung Cancer

February 27th 2015

Checkpoint Inhibition for Mesothelioma, Thymic Malignancies

February 27th 2015

Necitumumab in Squamous NSCLC

February 27th 2015

Ramucirumab in Metastatic NSCLC

February 27th 2015

Maintenance Combination Therapy in NSCLC

February 27th 2015

Chemotherapy Regimens in Metastatic NSCLC

February 27th 2015

Treating Driver Mutation Negative NSCLC

February 27th 2015

Novel ALK Inhibitors in NSCLC With Brain Metastases

February 27th 2015

Treatments for ALK-Positive NSCLC

February 27th 2015

ALK Inhibition in NSCLC

February 27th 2015